Date: 2014-05-21
Type of information: Series A financing round
Company: Lysogene (France)
Investors: Bpifrance (France) Novo Seeds (Denmark) Sofinnova Partners (France)
Amount: €16.5 million
Funding type: series A financing round
Planned used: In 2013, Lyogene successfully completed a phase I-II study (Eudract 2010-019962-10 / NCT01474343) using its lead product in Sanfilippo patients. The funds raised will be used to expand the clinical studies for its main product developed for patients with Sanfilippo syndrome Type A, towards its marketing approval in Europe and the US. Funds will also allow the expansion of the pipeline with a second product targeting another genetic disease affecting the central nervous system.
Others: * On May 21, 2014, Lysogene, a gene therapy biotechnology company focused on the development of breakthrough treatments for severe genetic pathologies with central nervous system involvement, announced that it has closed a €16.5 million Series A financing. Further to its initial seed to the series A investment, Paris-based Sofinnova Partners led this financing round, becoming the firm’s main institutional investor. New and co-lead investors include Bpifrance, through its Innobio fund, and Novo Seeds, part of Novo A/S. Rafaèle Tordjman, Chahra Louafi and Henrijette Richter, respectively as representatives of Sofinnova Partners, Innobio and Novo A/S, will sit on the board. The firm is specialised in intracerebral gene therapy aimed at treating neuro-degenerative diseases, such as Sanfilippo syndrome Type A. Sanfilippo syndrome is a lysosomal storage disease stemming from a deficiency in a particular enzyme, for which there is currently no treatment.
Therapeutic area: Rare diseases
